comparemela.com

Latest Breaking News On - Sarah boyce - Page 1 : comparemela.com

Softball: PIAA champ Blue Mountain proves too much for Pope John Paul II in PIAA 4A quarterfinal

Senior pitcher and slugger Marla Freiwald and reigning PIAA Class 4A champion Blue Mountain continued their repeat quest on Thursday at Patriots Park in Allentown with a six inning, 13-3 victory over District 1 champion Pope John Paul II.

Molly-houchins
Elle-walasavage
Charlie-hallman
Mike-rollman
Addyson-fishburn
Anna-borden
Lexi-dibricida
Rylee-derecola
Pope-john-paul
Steve-faella
Marla-freiwald
Sarah-boyce

Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sarah Boyce Sells 28,000 Shares

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CEO Sarah Boyce sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $27.42, for a total value of $767,760.00. Following the completion of the transaction, the chief executive officer now directly […]

United-states
America
Sarah-boyce
Vanguard-group-inc
Securities-exchange-commission
Raymond-james-financial-services-advisors-inc
Nasdaq
Cantor-fitzgerald
Avidity-biosciences-company-profile
Avidity-biosciences-inc
Mirae-asset-global-investments-co
Needham-company

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $41.33 Consensus PT from Brokerages

Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last […]

United-states
China
America
Sarah-boyce
Arthura-levin
Quadrant-capital-group
Daiwa-securities-group-inc
Needham-company
Nisa-investment-advisors
Cantor-fitzgerald
China-universal-asset-management-co
Securities-exchange-commission

Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Rating of "Buy" by Brokerages

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is […]

United-states
America
Arthura-levin
Sarah-boyce
Avidity-biosciences-inc
Vanguard-group-inc
Needham-company
Nasdaq
Cantor-fitzgerald
Avoro-capital-advisors
Pricet-rowe-associates-inc
Avidity-biosciences

Avidity Biosciences (NASDAQ:RNA) Releases Earnings Results, Beats Expectations By $0.02 EPS

Avidity Biosciences (NASDAQ:RNA – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.02, Zacks reports. Avidity Biosciences had a negative net margin of 2,103.78% and a negative return on equity of 37.98%. The company had revenue of […]

United-states
America
Michaelf-maclean
Sarah-boyce
Avidity-biosciences-inc
Cantor-fitzgerald
Avidity-biosciences-company-profile
Needham-company
Avidity-biosciences
Get-free-report
Avidity-biosciences-daily

vimarsana © 2020. All Rights Reserved.